Printer Friendly
The Free Library
21,440,732 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Browse Biotechnology industry topic

Product development subtopic

 

Articles

1-300 out of 600 article(s) nextnext page
Title Author Type Date Words
Prionics and Bio-X Diagnostics Form Strategic Partnership. May 13, 2013 513
RNL BIO Co. Ltd. Files IND To Commence Phase II Clinical Trial Of RNL-JointStem For Osteoarthritis In The United States. May 2, 2013 886
RNL BIO Co. Ltd. Files IND To Commence Phase II Clinical Trial Of RNL-JointStem For Osteoarthritis In The United States. May 2, 2013 881
Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia. Apr 26, 2013 629
NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting. Apr 8, 2013 1154
NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer. Apr 4, 2013 938
NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer. Apr 2, 2013 1315
Oncolytics Biotech[R] Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN[R] in Squamous Cell Lung Cancer. Mar 28, 2013 908
Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S' Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials. Mar 27, 2013 1668
The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology's CYT003 for the Treatment of Allergic Asthma. Clinical report Mar 13, 2013 975
DCVax-Direct Phase I/II Trial For All Inoperable Solid Tumors Is Expected To Produce Ongoing Results In 2013. Mar 5, 2013 1086
Araxes Pharma Enters Into Cancer Drug Discovery and Development Agreement With Janssen Biotech. Feb 27, 2013 542
Valent BioSciences to Sell Pace International Preharvest Products through Valent U.S.A. Corporation. Feb 27, 2013 768
Avraham Pharmaceuticals Closes an Additional Investment Round of Approximately $6 Million by Yissum, Pontifax and Clal Biotechnology Industries. Feb 21, 2013 1005
Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group. Feb 19, 2013 862
ACT's Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company's hESC-derived Cells to Treat Severe Myopia. Feb 11, 2013 1064
Oncolytics Biotech[R] Inc. Announces Additional Positive REOLSYIN[R] Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung. Report Feb 8, 2013 836
Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A. Feb 6, 2013 989
Daiichi Sankyo and Arqule Enroll First Hepatocellular Carcinoma (HCC) Patient into Global Phase 3 Trial for Tivantinib. Jan 31, 2013 1465
Daiichi Sankyo and ArQule Enroll First Hepatocellular Carcinoma Patient into Global Phase 3 Trial for Tivantinib. Jan 31, 2013 1468
RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program. Jan 30, 2013 748
Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition. Jan 30, 2013 1483
Alnylam and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer. Jan 30, 2013 2244
Seattle Genetics Announces Data from ASG-5ME Phase I Clinical Trial for Pancreatic Cancer. Jan 25, 2013 1237
Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS[R] (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL). Jan 24, 2013 2062
Surviving BioTech: How the Game is Played - Phase Funding, Drug Approvals and Resulting Revenue. Jan 14, 2013 739
Surviving BioTech: How the Game is Played - Phase Funding, Drug Approvals and Resulting Revenue. Jan 14, 2013 745
Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial with Tivantinib in Colorectal Cancer. Jan 11, 2013 1802
Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer. Jan 11, 2013 767
Spectrum Pharmaceuticals Announces Positive RenaZorb[R] Phase 1 Clinical Data Demonstrating Robust Activity in Easy-to-Swallow Pill Formulation. Jan 7, 2013 1182
Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR). Jan 3, 2013 2205
Fibrocell Science, Inc. to Initiate Phase II Clinical Trial for Restrictive Burn Scars. Medical condition overview Dec 17, 2012 1044
ACT Announces Completion of Higher-Dosage Cohort in European Clinical Trial for Stargardt's Macular Dystrophy. Dec 17, 2012 785
ArQule Enrolls First Patient in Phase 1 Trial with ARQ 087, an FGFR Inhibitor. Dec 13, 2012 825
XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris. Dec 12, 2012 731
Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis. Report Dec 10, 2012 909
Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS[R] (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma at ASH Annual Meeting. Dec 10, 2012 1955
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS[R] (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting. Dec 10, 2012 2212
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology. Clinical report Dec 10, 2012 2939
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS[R] (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas (MTCL). Dec 9, 2012 2103
NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer[R] NOX-H94. Dec 4, 2012 1060
Profectus BioSciences' Vesicular Stomatitis Virus-Vectored HIV-1 Vaccine Safe and Immunogenic in Government Sponsored Phase 1 Trial. Dec 4, 2012 1174
Aduro Announces Completion of Enrollment in Phase 2 Clinical Trial. Nov 29, 2012 399
BioTime CEO Dr. Michael West to Present at World Stem Cell Summit 2012. Nov 29, 2012 824
ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical Trials. Nov 28, 2012 1080
Cardio3 BioSciences Receives Authorization to Begin World's First Phase III Clinical Trial in Regenerative Medicine for Heart Failure. Nov 22, 2012 1027
Cardio3 BioSciences Receives Authorization to Begin World's First Phase III Clinical Trial in Regenerative Medicine for Heart Failure. Nov 22, 2012 1032
Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial. Nov 19, 2012 771
CytoDyn Announces Phase IIB Clinical Trial Agreement with Dr. Jeffrey Jacobson, Drexel University College of Medicine. Nov 16, 2012 1275
Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia. Nov 14, 2012 1999
AtheroNova Announces Milestone Filing of IND in Russian Federation. Nov 13, 2012 940
Generex Provides Update on Company Initiatives Including the AE37 Breast Cancer Vaccine Program. Nov 13, 2012 958
Advanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration Trials. Nov 8, 2012 1066
Pharming, Santarus report encouraging Phase III results for Ruconest in angioedema. Nov 7, 2012 191
Northwest Bio Collaborating With Leading UK Cancer Institutions For DCVax-Direct Trial. Nov 6, 2012 1260
Northwest Bio Collaborating With Leading UK Cancer Institutions For DCVax-Direct Trial. Nov 6, 2012 1295
Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma. Financial report Nov 2, 2012 819
Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS[R] in Previously Untreated Advanced Hodgkin Lymphoma. Nov 1, 2012 1754
ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Complete Second Patient Cohort in Clinical Trial for Dry AMD. Nov 1, 2012 798
Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the Treatment of Glaucoma. Financial report Nov 1, 2012 766
Disagreement with clinical trial methodology insufficient to claim fraud. Beck, Julie Nov 1, 2012 1001
Advaxis Updates Phase 2 Cervical Cancer Trial Data. Oct 31, 2012 1130
Enlivex Therapeutics Announces Positive Results in Completion of Clinical Trial for the Treatment of Bone Marrow Transplant Recipients. Clinical report Oct 24, 2012 1121
SARcode Bioscience Announces Positive Topline Results from Phase 3 Dry Eye Study of Lifitegrast. Oct 23, 2012 937
GlycoMimetics Announces Publication in Nature Medicine of Preclinical Data for Its GMI-1070 Drug Candidate. Oct 22, 2012 377
Millennium Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis. Oct 19, 2012 774
Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS[R] as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and Over. Oct 17, 2012 1576
PROLOR Biotech Announces Positive Results From Preclinical Toxicology Study Of Its Reversible-Pegylation Platform Technology. Oct 16, 2012 1118
ArQule and Daiichi Sankyo Reach Agreement with FDA on Special Protocol Assessment for Phase 3 Trial of Tivantinib in Hepatocellular Carcinoma. Clinical report Oct 16, 2012 1177
Pharmacyclics Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial. Oct 15, 2012 1202
ACT Announces Approval to Treat Additional Stargardt's Disease Patients with Higher RPE Dosage in Both U.S. and European Clinical Trials. Oct 9, 2012 922
Ingenuity Systems to Partner with Life Technologies to Develop Solutions for Interpreting Clinical Diagnostic Tests. Oct 3, 2012 728
XBiotech Receives Fast Track Designation from FDA for Anti-Cachexia Drug Xilonix(TM). Oct 3, 2012 744
TaiGen and Medigen of Taiwan to be in cross-strait drug project. Wang, Andrew Brief article Oct 2, 2012 204
Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012. Sep 30, 2012 1096
NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer[R]. Sep 26, 2012 1200
Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS[R] for Post-Transplant Patients with Hodgkin Lymphoma. Sep 25, 2012 1725
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program. Sep 24, 2012 1248
Maxwell Biotech Venture Fund Invests in POC Clinical Program of a New Anti-Tumor Drug Candidate MBC-11 Targeting Metastatic Bone Disease. Company overview Sep 24, 2012 1132
YM BioSciences Reports Fiscal 2012 Operational and Financial Results. Financial report Sep 21, 2012 17708
Research and Markets: Exelixis Inc. - Company Analysis: Assess the Potential of Cabozantinib Based on Market Size, Phase III Results, and Future Indications. Sep 21, 2012 345
Proteonomix Announces Agreement with the University of Medicine and Dentistry of New Jersey (UMDNJ) to Conduct a Phase 1 Trial with UMK-121 in End-Stage Liver Disease. Sep 14, 2012 764
China : MEDIMMUNE forms JV with WUXI APPTEC to develop new biologic. Sep 13, 2012 157
China : CHINA DEAL is signed by MedImmune. Sep 13, 2012 338
China,United States : Medimmune And Wuxi Apptec Announce Joint Venture To Develop Novel Biologic For Chinese Market. Company overview Sep 10, 2012 424
MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic for Chinese Market. Sep 10, 2012 1509
MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic for Chinese Market. Sep 10, 2012 1594
ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson's Disease Psychosis. Clinical report Sep 5, 2012 901
Alnylam Presents Complete Results from Phase IIb Trial with ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. Sep 4, 2012 2166
ImmunoGen, Inc. Announces Trastuzumab Emtansine (T-DM1) Significantly Improved Survival in the EMILIA Phase III Trial. Clinical report Aug 27, 2012 840
Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell Carcinoma. Aug 24, 2012 851
Kineta Announces Regulatory Clearance to Initiate a Phase 1 Clinical Trial for ShK-186. Aug 21, 2012 551
PhaseBio Pharmaceuticals Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes. Clinical report Aug 21, 2012 456
ACT Announces Scotland's NHS Lothian as Additional Site for EU Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration. Aug 20, 2012 843
Morphotek, Inc. Opens 60,000-square-foot Manufacturing Plant. Aug 14, 2012 650
United States : INVISTA and LanzaTech Sign Joint Development Agreement for Bio-Based Butadiene. Aug 14, 2012 391
INVISTA and LanzaTech Sign Joint Development Agreement for Bio-Based Butadiene. Aug 13, 2012 750
Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis. Aug 8, 2012 1446
Diffusion Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Brain Cancer Trial of TSC. Aug 1, 2012 494
Lixte Biotechnology Holdings Announces Increased Funding And FDA Allowance To Conduct A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100. Jul 31, 2012 668
ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration. Jul 30, 2012 891
Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting. Jul 30, 2012 1106
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis. Jul 26, 2012 976
Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored Trials in Non-Small Cell Lung Cancer and Multiple Myeloma. Jul 26, 2012 1187
Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias. Jul 25, 2012 814
IntelliCell BioSciences, Inc. New Lab at 460 Park Avenue, New York, NY is cGTP Compliant. Jul 24, 2012 1037
ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target. Jul 11, 2012 838
NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer[R] NOX-A12 for Treatment of Chronic Lymphocytic Leukemia. Jul 11, 2012 1109
FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes. Jul 11, 2012 679
ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD. Jul 9, 2012 916
Diamyd Medical Reports Results from Phase II Study in Cancer Pain. Clinical report Jul 3, 2012 1214
Clinical trials show promise in breast cancer treatment. Brief article Jul 1, 2012 239
3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin. Jun 28, 2012 538
ProtAffin AG starts Phase 1 study for lead product PA401 in inflammatory lung disease. Jun 27, 2012 810
Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status. Jun 25, 2012 1014
Seattle Genetics Highlights Updated Survival Data from ADCETRIS[R] Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma. Jun 14, 2012 1841
VaxInnate Begins Phase I Clinical Trial to Evaluate H5N1 Vaccine Candidate for Pandemic Avian Flu. Jun 12, 2012 730
Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma Presented at ASCO. Jun 11, 2012 1825
Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial. Jun 11, 2012 747
FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes. Jun 9, 2012 702
Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine. Jun 7, 2012 1013
Alnylam Completes Enrollment in Phase I Clinical Trial and Initiates Phase II Clinical Trial of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR). Jun 7, 2012 1720
Alnylam Presents Data from its Phase I Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting. Jun 4, 2012 2042
Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer. Jun 4, 2012 1178
Cabozantinib Meets Primary Endpoint of Progression Free Survival in Phase 3 Pivotal Trial in Medullary Thyroid Cancer. Jun 4, 2012 2176
Clinical drug trials challenging, rewarding. Jun 3, 2012 687
Advaxis to Report Updated Safety, Tumor Response, and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer at ASCO. Jun 3, 2012 1305
ImmunoGen, Inc. Announces Results from Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial. Jun 3, 2012 942
Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to Be Presented at ASCO. Jun 2, 2012 1744
Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to be Presented at ASCO. Jun 2, 2012 1748
Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting. Jun 2, 2012 879
Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIOTM* (teriflunomide) in Relapsing Multiple Sclerosis. Jun 1, 2012 1416
Advaxis Completes Enrollment in Phase 2 Cervical Cancer Study. Report May 29, 2012 791
Diamyd Medical's Phase II study in cancer pain fully recruited. May 22, 2012 1039
VBL Therapeutics Presents Positive Preclinical Data for VB-201 in Inflammatory Bowel Disease at Digestive Disease Week (DDW) 2012. May 21, 2012 760
Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting. Conference news May 18, 2012 1344
Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress. May 18, 2012 697
Arqule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-small Cell Lung Cancer. May 18, 2012 1431
ArQule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-Small Cell Lung Cancer. May 18, 2012 1338
Positive Phase 2 Clinical Data With Tivantinib in Hepatocellular Carcinoma to be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology. May 17, 2012 1505
Positive Phase 2 Clinical Data with Tivantinib in Hepatocellular Carcinoma to Be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology. Clinical report May 17, 2012 1492
Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers. May 15, 2012 1244
Alnylam Presents Final Results from a Phase I Clinical Trial of ALN-TTR01, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR). May 10, 2012 2387
Seattle Genetics Announces Data from Investigator Trial of ADCETRIS[TM] in Relapsed Cutaneous T-Cell Lymphoma. May 10, 2012 1784
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases% Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation. May 10, 2012 3198
Advaxis Announces Cancer Research UK Initiates Phase 1/2 Clinical Trial of ADXS-HPV for the Treatment of Head and Neck Cancer. May 8, 2012 998
Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS[TM] in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma. May 7, 2012 1836
Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating that Pentraxin-2 Suppressed Fibrosis, Neovascularization, and Vascular Leakage. May 7, 2012 781
ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for Dry Age-Related Macular Degeneration Using Human Embryonic Stem Cell-Derived RPE Cells. May 2, 2012 1006
Solazyme and Dow Enter into Contingent Global Commercial Offtake Agreement and Concurrently Sign Phase 2 Joint Development Agreement to Accelerate Commercialization of Bio-based Dielectric Insulating Fluids. May 2, 2012 1360
Institute in Philadelphia to participate in a clinical trial. Brief article May 1, 2012 190
Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease. Financial report May 1, 2012 692
ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt's Disease Patients in U.S. Trial. Apr 24, 2012 1072
Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif[R] in Phase III Trial. Apr 24, 2012 2977
ACT Announces Third Dry AMD Patient Treated in Clinical Trial. Apr 20, 2012 1127
Opexa to Hold Preliminary Investigator's Meeting for MS Trial at American Academy of Neurology Annual Meeting. Apr 19, 2012 1123
Viral Genetics April 2012 Shareholder Update Alerts Investors to Product Pipeline Expansion and Developments at Algal BioFuels Subsidiary. Apr 18, 2012 587
ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound. Apr 17, 2012 802
ACT Announces Second Patient with Dry AMD Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells. Apr 16, 2012 689
BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012. Apr 16, 2012 855
Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials. Financial report Apr 5, 2012 781
ACT Announces Approval of Bascom Palmer Eye Institute as Additional Site for Stem Cell Clinical Trial for dry Age-Related Macular Degeneration. Apr 4, 2012 1017
FYI from Human Genome Sciences: GlaxoSmithKline Announces Further Data from Phase 3 Trials of Albiglutide. Apr 3, 2012 629
Oncolytics Biotech[R] Inc. Completes Enrollment in First Stage of Phase III Study in Head and Neck Cancers. Report Apr 2, 2012 769
ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial. Mar 30, 2012 864
Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD). Mar 22, 2012 759
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug. Mar 20, 2012 871
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug. Mar 20, 2012 867
Alnylam Initiates Phase I Clinical Study of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR). Mar 19, 2012 2041
Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Mar 7, 2012 886
Millennium Initiates Pivotal Phase 3 Trial of MLN8237 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma. Mar 6, 2012 551
KYTHERA Biopharmaceuticals Announces Initiation of Pivotal U.S. Phase III Clinical Trials to Evaluate ATX-101 for Reduction of Submental Fat. Mar 5, 2012 1166
Vitiva and naturamed team up. Brief article Mar 1, 2012 224
Oncolytics Biotech[R] Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Prostate Cancer. Clinical report Feb 21, 2012 683
Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for Stargardt's Disease. Feb 15, 2012 1122
ACT Announces Third Patient with Stargardt's Disease Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells. Feb 13, 2012 925
Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration. Jan 17, 2012 1328
Three Adimab Antibodies Enter Human Clinical Trials. Jan 11, 2012 384
Cubist Pharmaceuticals and Hydra Biosciences Announce Plans to Begin Phase 1 Clinical Trial for Novel TRPA1 Modulator to Treat Acute Pain. Jan 10, 2012 1002
Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials. Clinical report Jan 9, 2012 2073
Alnylam Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidosis. Jan 6, 2012 2069
Acasti Pharma Initiates 2nd Phase 2 Clinial Study. Dec 31, 2011 642
ISRAEL : Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology. Dec 21, 2011 370
Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis. Dec 20, 2011 1434
Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology. Dec 20, 2011 2045
Bio-Path Holdings' Initial Phase I Data in Leukemia Clinical Trial Demonstrates That Its Neutral Lipid Delivery Technology Antisense Drug BP-100-1.01 (Liposomal Grb-2) is Well Tolerated with Activity Seen at Low Starting Dose. Dec 13, 2011 1107
Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS[TM] (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting. Dec 13, 2011 2220
Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc. Dec 8, 2011 1084
Alnylam Completes Enrollment in Phase IIb Study of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. Clinical report Nov 29, 2011 1526
Exelixis Announces Initiation of Phase 2 Investigator-Sponsored Trial of Cabozantinib in Women with Hormone Receptor-Positive Metastatic Breast Cancer and Bone Metastases. Nov 21, 2011 1722
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis. Nov 14, 2011 2109
Yissum, Pontifax, Clal Biotechnology Industries, TRDF and Other Investors Complete Additional Investment Round of $3 Million in Avraham Pharmaceuticals. Nov 14, 2011 956
Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease. Clinical report Nov 9, 2011 1053
Avila Therapeutics Presents Clinical and Preclinical Data on AVL-292 Showing Potential for the Treatment of Autoimmune Disease at the 2011 American College of Rheumatology Annual Scientific Meeting. Nov 8, 2011 523
KYTHERA Biopharmaceuticals Presents Long-Term Follow-up Study Results From Phase 2 Trials With ATX-101. Nov 7, 2011 1142
ACADIA Pharmaceuticals Advances AM-831 to Phase I Clinical Development in Collaboration with Meiji Seika Pharma. Nov 7, 2011 1126
Promedior Presents Preclinical Data at AASLD Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis and Has a Clear Hepatoprotective Effect. Nov 7, 2011 997
Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients. Nov 5, 2011 1921
Promedior Announces Presentation of Preclinical Data at AASLD Demonstrating that Pentraxin-2 Suppresses Liver Fibrosis. Nov 2, 2011 695
Biotech SIC to kick off operation on Nov. 1. Liu, Philip Brief article Oct 31, 2011 244
Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS[TM] in CD30-Positive Non-Lymphoma Malignancies. Oct 25, 2011 1220
Exelixis' Cabozantinib Meets Primary Endpoint in Phase 3 Clincial Trial for Medullary Thyroid Cancer. Clinical report Oct 24, 2011 1499
Alemtuzumab (Lemtrada[TM]*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study. Oct 22, 2011 2221
Oral Therapy Teriflunomide (Aubagio(TM)(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis. Oct 20, 2011 1810
BioCancell to Commence Enrollment of Phase IIb Pancreatic Cancer Clinical Trial. Oct 6, 2011 518
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio(TM)(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity. Oct 6, 2011 1781
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio(TM)(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity. Oct 5, 2011 1785
Research and Markets: UK and Ireland Biotechnology Sector: Clinical Phase Drug Development Pipeline. Oct 4, 2011 701
Initial Data from Bio-Path Holdings' Phase I Clinical Trial Accepted for Presentation at American Society of Hematology Annual Meeting. Oct 4, 2011 770
Santaris Pharma A/S to Report New Clinical Data From Miravirsen Phase 2a Study to Treat Hepatitis C in Late-Breaking Oral Presentation at the AASLD 2011 Annual Meeting. Clinical report Oct 3, 2011 1354
Sangamo BioSciences Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints. Oct 3, 2011 1503
Synageva BioPharma Expands International Clinical Trial for Infants with Lysosomal Acid Lipase Deficiency, a Lysosomal Storage Disorder. Sep 28, 2011 1139
ACT Receives Approval from Data and Safety Monitoring Board (DSMB) to Treat Next Patients in Stem Cell Clinical Trials. Sep 28, 2011 1395
Alnylam Initiates Phase I Clinical Study of ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia. Sep 26, 2011 2102
Abnova, Clearbridge tie up in cancer-diagnostic device market. Liang, Quincy Brief article Sep 23, 2011 232
ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe. Sep 22, 2011 1242
ConjuChem Initiates Phase 2 Study of Diabetes Drug. Sep 14, 2011 533
Alnylam Expands "Alnylam 5x15" RNAi Therapeutic Pipeline with ALN-APC, an RNAi Therapeutic Targeting Protein C for the Treatment of Hemophilia. Sep 8, 2011 2473
NOXXON initiates Phase I of NOX-H94 for Anemia of Chronic Disease. Sep 6, 2011 740
Enlivex completes Trial enrollment for GVHD in transplant. Aug 30, 2011 903
Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS[TM] in CD30-Positive Non-Hodgkin Lymphoma. Aug 23, 2011 816
First Cohort Successfully Completed in Bio-Path Holdings' Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia. Aug 11, 2011 1040
Oncolytics Biotech Clinical Trial Reports Positive Results. Aug 1, 2011 429
Alnylam Completes ALN-VSP Phase I Trial in Patients with Liver Cancer. Aug 1, 2011 1677
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment. Aug 1, 2011 1871
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada[TM] (*)) in Multiple Sclerosis. Jul 11, 2011 1870
Alnylam Files Clinical Trial Application (CTA) for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia. Jul 11, 2011 1815
Almac Expands Global Coverage by Adding Depots for Clinical Trial Supply Distribution to the Asia Pacific Region. Jun 29, 2011 518
Sinovac Commences Phase II Clinical Trial for EV71 Vaccine. Jun 28, 2011 1207
Diamyd Medical: Diamyd Presents Detailed Results of European Phase III Study. Jun 28, 2011 1223
Pharmaceutical Industry Veterans Establish BioEndpoint Consulting to Offer Strategic Insight and Expertise in Commercialization Processes and Drug Development. Jun 27, 2011 418
Diamyd Medical: Diamyd Initiates Closure of US Phase III study. Jun 23, 2011 1044
MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28. Jun 23, 2011 513
Avila Therapeutics Presents Preclinical Data with AVL-292, its Btk Inhibitor, Demonstrating Suppression of Autoimmune Disease Activity. Jun 23, 2011 692
Synageva BioPharma Receives FDA Fast Track Designation for SBC-102 for Lysosomal Acid Lipase Deficiency. Jun 23, 2011 1329
Clinical Development Plan for Pediatric Use of PROLOR Biotech's Long-Acting Human Growth Hormone has Been Accepted for Review by European Medicines Agency. Jun 20, 2011 1122
Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes. Clinical report Jun 14, 2011 473
INVO Bioscience Announces Planned Submission To ANVISA For Brazilian Approval Following Completion of Clinical Trial. Jun 14, 2011 1215
Third Annual Diversity Summit at the 2011 BIO Convention Convenes to Discuss Disparities in Clinical Trials and Healthcare. Jun 14, 2011 777
Interim Data From Phase 2 Trial of AC220 Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia With FLT3-ITD Activating Mutations. Jun 13, 2011 1358
Interim Data from Phase 2 Trial of AC220 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia with FLT3-ITD Activating Mutations. Jun 13, 2011 1344
Millennium and Seattle Genetics Present Clinical Data on ADCETRIS[TM] (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting. Jun 10, 2011 1411
Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual Meeting. Jun 6, 2011 1156
Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer. Jun 6, 2011 2855
ImmunoGen, Inc. Announces Positive Clinical Data Presented on IMGN901 in the Treatment of Multiple Myeloma. Jun 5, 2011 898
Alnylam Presents Phase I Data for ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting. Jun 4, 2011 2499
Profectus BioSciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Immunogenicity of a Vesicular Stomatitis Virus-vectored HIV-1 Vaccine. Jun 1, 2011 741
The ACTG Immunizes First Subject in Clinical Trial of Profectus BioSciences' Therapeutic HIV DNA Vaccine. May 25, 2011 996
Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology. May 23, 2011 1532
VBL Therapeutics Presents Preclinical Data for VB-111 at the 14th Annual ASGCT Meeting. May 19, 2011 706
Cannabis Science Announces Planned Thailand Business Partnership and Clinical Trials for Medical Marijuana. May 18, 2011 542
Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell Lymphoma. May 17, 2011 1692
TTC's Standard of Care Data Ensures Savings for Most Clinical Trial Procedures, Not Just Oncology. May 12, 2011 672
Santaris Pharma A/S Advances a Second Drug From Its Cardiometabolic Program, SPC4955, Inhibiting apoB, into Phase 1 Clinical Trials for the Treatment of High Cholesterol. May 11, 2011 1212
Can-Fite Announces a Promising Interim Analysis Data of Its Phase I/II Liver Cancer Study with the CF102 Drug. May 11, 2011 466
Diamyd Medical: Diamyd Reports Initial Results from European Phase III Trial in Patients Newly Diagnosed with Type 1 Diabetes. Clinical report May 9, 2011 989
Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization in Retinal Diseases. May 4, 2011 1005
Santaris Pharma A/S Advances New Cholesterol-Lowering Drug, SPC5001 Inhibiting Exciting New Target PCSK9, Into Phase 1 Clinical Trials for the Treatment of High Cholesterol. May 4, 2011 1291
Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002. May 2, 2011 575
Cellceutix CEO, Leo Ehrlich, Conducts Interview with "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board. Apr 18, 2011 1002
KBC to review Galapagos rating after discontinued RA clinical trials. Apr 15, 2011 139
Galapagos' shares plunge on aborted clinical trial. Apr 15, 2011 116
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease. Apr 14, 2011 1714
Liver Cell Infusion Performed for First Time in the United States on Child With Life-Threatening Disorder. Apr 14, 2011 1077
VERONA PHARMA PLC - First COPD Trial with RPL554 Begins in Rome. Apr 12, 2011 674
Diamyd Medical: Diamyd Results from Phase I Clinical Trial in Cancer Pain Published in Annals of Neurology. Apr 11, 2011 773
Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy Of Neurology. Apr 7, 2011 1696
Data from Two Mipomersen Phase 3 Trials Presented at ACC. Apr 5, 2011 2650
Cardio3 BioSciences Announces Results of the C-Cure(R) Phase II Clinical Trial at the 60th Annual American College of Cardiology Meeting. Apr 5, 2011 1416
Alnylam Completes Enrollment in ALN-VSP Phase I Clinical Trial. Mar 31, 2011 1383
SINOVAC BIOTECH SUBMITS CLINICAL TRIAL APPLICATION FOR PCV. Mar 29, 2011 893
BioInvent International AB: First Patient Dosed in Phase II Clinical Trial for Novel Cardiovascular Drug, BI-204. Clinical report Mar 14, 2011 681
Euthymics Bioscience Initiates Triade Trial for Major Depression. Mar 14, 2011 920
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris. Clinical report Mar 10, 2011 674
Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group. Mar 10, 2011 1026
Phase III Study of Lucentis Showed Rapid Vision Improvements Sustained for Two Years in Patients with Diabetic Macular Edema. Mar 10, 2011 2209
Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV). Mar 3, 2011 1382
Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL. Mar 1, 2011 1011
Bayhill Therapeutics Announces the Successful Clearance of an IND for BHT-3034 for the Treatment of Myasthenia Gravis. Mar 1, 2011 577
Efficacy studies of the future. Mar 1, 2011 1414
PolyMedix Successfully Completes Phase 1 Exposure Escalation Safety Study With PMX-30063 Antibiotic. Feb 24, 2011 1450
Three-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Further Improvement Across All Endpoints. Feb 18, 2011 1655
CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis. Feb 17, 2011 550
Cabozantinib (XL184) Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Castration-Resistant Prostate Cancer. Feb 17, 2011 2414
Diamyd Medical: Last Patient Completes the EU Phase III Study of Diamyd[R] Antigen Based Therapy for Type 1 Diabetes. Clinical report Feb 14, 2011 908
Diamyd Medical: Diamyd Phase II Study in Cancer Pain Posted on ClinicalTrials.gov. Clinical report Feb 10, 2011 592
PolyMedix Initiates Phase 2 Clinical Trial with Novel Heptagonist, PMX-60056. Feb 9, 2011 1136
Human Genome Sciences and GlaxoSmithKline Announce Publication of BLISS-52 Phase 3 Study Results for BENLYSTA[R] in The Lancet. Clinical report Feb 7, 2011 763
MACROGENICS BEGINS PHASE I CLINICAL TRIAL OF MGAH22. Feb 1, 2011 662
SINOVAC GETS SFDA APPROVAL TO BEGIN EV71 VACCINE TRIALS. Feb 1, 2011 724
Maxygen Announces Initiation of Phase I Clinical Trial Under Perseid's Collaboration with Astellas for CTLA4-Ig Program. Jan 31, 2011 1079
Verona Pharma Applies for Approval to Test RPL554 in UK Clinical Trials. Jan 31, 2011 554
Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial. Jan 28, 2011 672
INVO Bioscience Announces Commencement of Clinical Trial in Brazil to Obtain ANVISA Approval. Jan 25, 2011 1284
Diamyd Medical: Diamyd Starts Phase II Study in Cancer Pain. Jan 17, 2011 758
Independent Data Safety Monitoring Board Gives "Go-Ahead" to Complete Dosing in First Leg of Advaxis' Phase II Cervical Dysplasia Trial. Jan 14, 2011 685
EHSI Eyes Opportunity for NASA Bioreactor in OceanBASIS Project. Jan 13, 2011 757
Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient into Global Phase 3 Trial for ARQ 197. Clinical report Jan 12, 2011 1461
Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197. Jan 12, 2011 1673
Sangamo BioSciences Announces Completion of Enrollment of Phase 2b Clinical Trial in Diabetic Neuropathy. Jan 10, 2011 2017

Terms of use | Copyright © 2013 Farlex, Inc. | Feedback | For webmasters | Submit articles